Literature DB >> 8228792

Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems.

W Knisel1, A Di Nicuolo, M Pfohl, H Müller, T Risler, M Eggstein, E Seifried.   

Abstract

OBJECTIVE: Immunoadsorption (IMA) and dextran sulfate adsorption (DSA) are two methods for selective extracorporeal elimination of low-density lipoproteins which are known as LDL apheresis. Their influence on haemostasis until now is widely unknown.
DESIGN: The effects of both LDL apheresis procedures on the coagulation and fibrinolytic systems were compared amongst five patients treated with IMA and four patients who received a DSA therapy.
SUBJECTS: All patients with severe heterozygous familial hypercholesterolaemia were participants in a long-term LDL apheresis programme with treatments every 1-2 weeks. INTERVENTION: Combined anticoagulation with heparin and citrate in IMA, and also heparin exclusively in DSA were used for the extracorporeal circulation. MEASURES: Blood samples were taken immediately before and after a single LDL apheresis and five times during the weekly interval until the next therapy.
RESULTS: DSA had a significantly greater effect on standard clotting tests than IMA at the end of plasma therapy despite identical dosages of heparin. DSA caused a considerable reduction of the coagulation factors V, VIII:C, vWF:Ag, XI, XII, and prekallikrein by 48-99% at the end of apheresis treatment whereas only factor VIII:C showed a marked decrease of 72% after IMA. All abnormalities of the global coagulation tests and of most clotting factors were restored 1 day after treatment in both procedures followed by a moderate rebound phenomenon of single coagulation factors during the next few days in IMA-treated patients.
CONCLUSION: DSA exerts a more profound effect on the coagulation system than IMA by a substantial co-elimination of various clotting factors in addition to the desired removal of atherogenic lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228792     DOI: 10.1111/j.1365-2796.1993.tb00781.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  10 in total

1.  LDL-apheresis therapy.

Authors:  Patrick M Moriarty
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

Review 2.  Lipoprotein apheresis.

Authors:  Vijay G Bhoj; Bruce S Sachais
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

3.  Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.

Authors:  Eri Muso; Masatoshi Mune; Tsutomu Hirano; Motoshi Hattori; Kenjiro Kimura; Tsuyoshi Watanabe; Hitoshi Yokoyama; Hiroshi Sato; Shunya Uchida; Takashi Wada; Tetsuo Shoji; Yukio Yuzawa; Tsukasa Takemura; Satoshi Sugiyama; Yoshiki Nishizawa; Satoru Ogahara; Noriaki Yorioka; Soichi Sakai; Yosuke Ogura; Susumu Yukawa; Yasuhiko Iino; Enyu Imai; Seiichi Matsuo; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-06-17       Impact factor: 2.801

4.  Correction of erythrocyte shape abnormalities in familial hypercholesterolemia after LDL-apheresis: does it influence cerebral hemodynamics?

Authors:  A Iannuzzi; G Bianciardi; F Faccenda; A Gnasso; N Scarpato; L Di Marino; G Iaccarino; C Simoes; G Sacchi; E Weber
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 5.  Applications of LDL-apheresis in nephrology.

Authors:  Shuzo Kobayashi
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

6.  Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low-density lipoproteins.

Authors:  W Knisel; M Pfohl; M Müller; I Besenthal; A di Nicuolo; W Voelker; T Risler; M Eggstein
Journal:  Clin Investig       Date:  1994-09

7.  Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles.

Authors:  Jiong-Wei Wang; Ya-Nan Zhang; Siu Kwan Sze; Sander M van de Weg; Flora Vernooij; Arjan H Schoneveld; Sock-Hwee Tan; Henri H Versteeg; Leo Timmers; Carolyn S P Lam; Dominique P V de Kleijn
Journal:  Int J Mol Sci       Date:  2017-12-29       Impact factor: 5.923

8.  Role of lipid apheresis in changing times.

Authors:  Peter Schuff-Werner; Sebastian Fenger; Peter Kohlschein
Journal:  Clin Res Cardiol Suppl       Date:  2012-06

9.  A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome.

Authors:  Eri Muso; Masatoshi Mune; Tsutomu Hirano; Motoshi Hattori; Kenjiro Kimura; Tsuyoshi Watanabe; Hitoshi Yokoyama; Hiroshi Sato; Shunya Uchida; Takashi Wada; Tetsuo Shoji; Tsukasa Takemura; Yukio Yuzawa; Satoru Ogahara; Satoshi Sugiyama; Yasuhiko Iino; Soichi Sakai; Yousuke Ogura; Susumu Yukawa; Yoshiki Nishizawa; Noriaki Yorioka; Enyu Imai; Seiichi Matsuo; Takao Saito
Journal:  Nephron Extra       Date:  2015-08-29

10.  Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia.

Authors:  Julia Lischka; Klaus Arbeiter; Charlotte de Gier; Andrea Willfort-Ehringer; Nina-Katharina Walleczek; Renata Gellai; Michael Boehm; Albert Wiegman; Susanne Greber-Platzer
Journal:  BMC Pediatr       Date:  2022-03-12       Impact factor: 2.567

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.